These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 8721275)

  • 1. Pharmacokinetics of moxisylyte in healthy volunteers after intravenous infusion and intracavernous administration with and without a penile tourniquet.
    Costa P; Bressolle F; Mottet N; Rouzier-Panis R; Navratil H; Marquer C
    Ther Drug Monit; 1996 Apr; 18(2):135-44. PubMed ID: 8721275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of moxisylyte in healthy volunteers after intracavernous injection of increasing doses.
    Bressolle F; Costa P; Rouzier-Panis R; Marquer C
    Eur J Clin Pharmacol; 1996; 49(5):411-5. PubMed ID: 8866639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of moxisylyte in healthy volunteers after intravenous and intracavernous administration.
    Costa P; Bressolle F; Sarrazin B; Mosser J; Galtier M
    J Pharm Sci; 1993 Jul; 82(7):729-33. PubMed ID: 8103112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of moxisylyte in healthy volunteers after intravenous and oral administration.
    Costa P; Bressolle F; Bromet-Petit M; Mosser J; Sarrazin B
    J Pharm Sci; 1992 Dec; 81(12):1223-6. PubMed ID: 1491345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Moxisylyte plasma kinetics in humans after intracavernous administration.
    Costa P; Bressolle F; Sarrazin B; Mosser J; Navratil H; Galtier M
    Biopharm Drug Dispos; 1992 Dec; 13(9):671-9. PubMed ID: 1467454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-performance liquid chromatographic determination of the conjugate metabolites of moxisylyte in human plasma and urine.
    Marquer C; Bressolle F
    J Chromatogr B Biomed Sci Appl; 1997 Apr; 691(2):389-96. PubMed ID: 9174276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple-dose pharmacokinetics of moxisylyte after oral administration to healthy volunteers.
    Costa P; Bressolle F; Jarroux E; Sarrazin B; Mosser J; Navratil H; Galtier M
    J Pharm Sci; 1993 Sep; 82(9):968-71. PubMed ID: 8229699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effectiveness of and tolerance to intracavernous injection of moxisylyte in patients with erectile dysfunction: effect/dose relationship versus placebo].
    Navratil H; Costa P; Louis JF; Andro MC; Saur P
    Prog Urol; 1995 Nov; 5(5):690-6. PubMed ID: 8580980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolism of 14C-moxisylyte in hairless rat. Comparison between intravenous and oral route.
    Neau B; Roux J; Lambrey B; Courtiol C; Marty JP; Grislain L
    Arzneimittelforschung; 1995 Jan; 45(1):10-4. PubMed ID: 7893260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolism of thymoxamine. II. Studies with 14C-thymoxamine in man.
    Vollmer KO; Poisson A
    Eur J Drug Metab Pharmacokinet; 1985; 10(1):71-6. PubMed ID: 3161739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolism of 14C-moxisylyte after percutaneous application in hairless rat.
    Neau B; Roux J; Marty JP
    Arzneimittelforschung; 1998 Jan; 48(1):34-8. PubMed ID: 9522028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of thymoxamine in rabbits after ophthalmic and intravenous administration.
    Aldana I; González-Peñas E; Fos D; Bruseghini L; Esteras A; Ceppi Monti N; Gianesello V
    Eur J Drug Metab Pharmacokinet; 1994; 19(2):79-83. PubMed ID: 8001598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of a prodrug thymoxamine: dose-dependence of the metabolite ratio in healthy subjects.
    Marquer C; Trouvin JH; Lacolle JY; Dupont C; Jacquot C
    Eur J Drug Metab Pharmacokinet; 1991; 16(3):183-8. PubMed ID: 1839981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Moxisylyte: a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in impotence.
    Marquer C; Bressolle F
    Fundam Clin Pharmacol; 1998; 12(4):377-87. PubMed ID: 9711459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of intracavernous injections using an alpha-blocking agent.
    Buvat J; Lemaire A; Buvat-Herbaut M; Marcolin G
    J Urol; 1989 Jun; 141(6):1364-7. PubMed ID: 2524603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics study of 14C-moxisylyte after percutaneous application to hairless rat.
    Neau B; Roux J; Courtiol C; Lambrey B; Marty JP
    Arzneimittelforschung; 1995 Nov; 45(11):1161-5. PubMed ID: 8929231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intracavernous pharmacotherapy: comparison of Moxisylyte and prostaglandin E1.
    Buvat J; Lemaire A; Herbaut-Buvat M
    Int J Impot Res; 1996 Jun; 8(2):41-6. PubMed ID: 8858388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is the volume injected a parameter likely to influence the erectile response observed after intracavernous administration of an alpha-blocking agent?
    Costa P; Sarrazin B; Bressolle F; Mottet N; Louis JF; Saudubray F; Navratil H
    Eur Urol; 1993; 24(1):43-7. PubMed ID: 8365438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of the method of intracavernous injection on penile rigidity: a possible pharmacokinetic explanation.
    de Meyer JM; Oosterlinck W
    Urology; 1997 Feb; 49(2):248-52. PubMed ID: 9037289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficacy and tolerance of intracavernous injection of moxisylyte in patients with erectile dysfunction: double-blind placebo-controlled study].
    Hermabessiere J; Costa P; Andro MC
    Prog Urol; 1995 Dec; 5(6):985-91. PubMed ID: 8777409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.